Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
Fish and Richardson
McKinsey
UBS
Julphar
Chubb
QuintilesIMS
US Army
Chinese Patent Office

Generated: August 18, 2017

DrugPatentWatch Database Preview

Apopharma Inc Company Profile

« Back to Dashboard

What is the competitive landscape for APOPHARMA INC, and when can generic versions of APOPHARMA INC drugs launch?

APOPHARMA INC has two approved drugs.

There are two US patents protecting APOPHARMA INC drugs on APOPHARMA INC drugs in the past three years.

There are thirty-eight patent family members on APOPHARMA INC drugs in twenty-five countries.

Summary for Applicant: Apopharma Inc

Patents:2
Tradenames:1
Ingredients:1
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apopharma Inc
FERRIPROX
deferiprone
TABLET;ORAL021825-001Oct 14, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for APOPHARMA INC drugs

Drugname Dosage Strength Tradename Submissiondate
deferiprone
Tablets500 mg
FERRIPROX
1/29/2016

International Patent Family for Apopharma Inc Drugs

Country Document Number Estimated Expiration
Mexico2010011701► Subscribe
China101380322► Subscribe
Hong Kong1152871► Subscribe
Spain2324978► Subscribe
Costa Rica11744► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Healthtrust
Express Scripts
Julphar
Colorcon
US Army
Merck
Queensland Health
McKinsey
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot